Trials / Completed
CompletedNCT00998751
Masitinib in Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)
Phase 2 Study of Oral AB1010 in Non Pre-treated, Inoperable Patients With Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- AB Science · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective is to evaluate the efficacy and safety of AB1010 at 7.5 mg/kg/day in the treatment of non pre-treated, inoperable patients with locally advanced/metastatic GIST.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | oral masitinib | 7.5 mg/kg/day |
Timeline
- Start date
- 2005-06-01
- Primary completion
- 2013-06-01
- Completion
- 2013-06-01
- First posted
- 2009-10-20
- Last updated
- 2018-12-11
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT00998751. Inclusion in this directory is not an endorsement.